(acquired by IBM)
|$2.18 to $73.20||3487%|
|$2.35 to $24.08||925%|
|Cellstar||$1.44 to $13.50||837%|
|Iomega||$3.25 to $13.90||328%|
|Nanophase||$3.75 to $16.75||347%|
|Immunomedics||$1.44 to $29.12||1922%|
|Total Renal Care||$3.12 to $26.95||741%|
|Voxware||$ .90 to $10.31||1046%|
|Corvas||$3.00 to $23.25||675%|
|Cytogen||$2.12 to $17.50||725%|
|Verilink||$3.00 to $14.62||387%|
|GeneLabs||$2.31 to $10.72||364%|
WE CLOSED ATOSSA GENETICS AT $1.93 CENTS FOR A 106% GAIN!
WE CLOSED SUNESIS PHARMACEUTICAL AT 64 CENTS FOR A 60% GAIN!
ALSO, WE CLOSED AGEX THERAPEUTICS AT $4.02 FOR A 55% GAIN!
The late-January Newsletter is now live on the site! Featured are two biotech's. One focuses on cancer and has collaborations with Novartis and Genentech and trades at around 60 cents; while the other, also a biotech, trades at around $2.00 and focuses on hearing disorders.
Featured in the early to mid-February issue will be a drug maker developing therapies for ADHD trading at around $2.00; and a biotech that has collaborations with Novartis and Merck and trades in the area of $2.55.
It looks like we have almost reached a bottom in the recent market sell off. You can get back into the market now or wait until it's 10% to 15% higher. Which makes the more sense?
"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"
— B.K. (Contractor in Saudi Arabia)